PT-141, also known by its research name bremelanotide, is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors, particularly the MC3R and MC4R subtypes. Originally derived from the superpotent melanocortin analog Melanotan II, PT-141 differs from its parent compound in that it lacks the linear tail, making it a cyclic lactam peptide with distinct pharmacological properties. It has been studied in preclinical models for its interactions with the central melanocortin signaling system.
The Melanocortin System
The melanocortin system is a neuroendocrine signaling network consisting of five G protein-coupled receptor subtypes (MC1R through MC5R) and their endogenous peptide ligands, which are derived from the precursor protein proopiomelanocortin (POMC). The melanocortin receptors are distributed across diverse tissues and mediate a wide range of physiological functions. MC1R is primarily expressed in melanocytes and is involved in pigmentation. MC2R is the ACTH receptor in adrenal cortex. MC3R and MC4R are expressed in the central nervous system and play roles in energy homeostasis and neural signaling. MC5R is found in exocrine glands.
PT-141 is of particular research interest because of its activity at MC3R and MC4R, both of which are expressed in brain regions including the hypothalamus, limbic system, and brainstem. These receptors are involved in complex integrative signaling pathways that regulate feeding behavior, energy expenditure, and autonomic function in preclinical models.
Receptor Binding Profile
In-vitro receptor binding studies have characterized PT-141 as a non-selective agonist with activity at multiple melanocortin receptor subtypes, with particular potency at MC3R and MC4R. Competitive binding assays using radiolabeled NDP-MSH (a reference melanocortin agonist) have demonstrated that PT-141 displaces the radioligand from MC4R with nanomolar affinity. Functional assays measuring cyclic AMP accumulation in cells expressing individual melanocortin receptor subtypes have confirmed agonist activity at MC1R, MC3R, MC4R, and MC5R, with minimal activity at MC2R.
This receptor binding profile distinguishes PT-141 from alpha-MSH and other endogenous melanocortin peptides. Researchers studying melanocortin receptor pharmacology have used PT-141 alongside selective agonists and antagonists to map the functional contributions of individual receptor subtypes to observed physiological responses in animal models.
CNS Signaling Research
The central mechanism of action of PT-141 has been a focus of preclinical investigation. Unlike compounds that act peripherally on vascular smooth muscle, PT-141 has been demonstrated to exert its effects through central nervous system pathways in animal studies. Research using c-Fos immunohistochemistry, a marker of neuronal activation, has shown that PT-141 administration in rodent models activates neurons in the paraventricular nucleus of the hypothalamus, the medial preoptic area, and other brain regions expressing melanocortin receptors.
Electrophysiological studies in brain slice preparations have demonstrated that melanocortin receptor activation modulates excitatory and inhibitory synaptic transmission in hypothalamic circuits. These studies have contributed to the understanding of how the melanocortin system integrates diverse neural inputs to coordinate physiological outputs, a fundamental question in neuroendocrinology research.
Preclinical Study Design Considerations
Researchers working with PT-141 in animal models should be aware of several important considerations. The peptide has been administered via subcutaneous and intranasal routes in preclinical studies. Dose-response relationships have been characterized in multiple species, with effective doses varying considerably between rodent and primate models. As with all melanocortin agonists, researchers should monitor for expected on-target effects including changes in pigmentation at the MC1R level, which can serve as a visible biomarker of melanocortin receptor activation.
PT-141 is supplied as a lyophilized powder and should be stored at negative twenty degrees Celsius. Reconstitution with bacteriostatic water produces a clear solution that should be refrigerated at two to eight degrees Celsius and used within three weeks. Purity and identity should be confirmed via HPLC and mass spectrometry with each lot.
Research Use Disclaimer
PT-141 is provided exclusively for in-vitro and preclinical research use. It is not sold for human consumption or therapeutic application. All pharmacological data presented in this article is derived from preclinical studies in cell culture systems and animal models. Researchers must ensure compliance with all applicable regulatory requirements and institutional oversight when incorporating PT-141 into experimental protocols.